(Q40405651)

20 September 2017

title

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia (English)

1 reference

20 September 2017

1 reference

Goemans BF

1

1 reference

20 September 2017

Zwaan CM

2

1 reference

20 September 2017

Miller M

3

1 reference

20 September 2017

Zimmermann M

4

1 reference

20 September 2017

Harlow A

5

1 reference

20 September 2017

Meshinchi S

6

1 reference

20 September 2017

Loonen AH

7

1 reference

20 September 2017

Hählen K

8

1 reference

20 September 2017

Reinhardt D

9

1 reference

20 September 2017

Creutzig U

10

1 reference

20 September 2017

Kaspers GJ

11

1 reference

20 September 2017

Heinrich MC

12

1 reference

20 September 2017

publication date

1 September 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

19

1 reference

20 September 2017

issue

9

1 reference

20 September 2017

page(s)

1536-1542

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403870

20 September 2017

exact match

0 references

cites work

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

KIT mutations are common in testicular seminomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

RAS mutations in pediatric leukemias with MLL gene rearrangements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

21 January 2018

Role of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

Definition of a standard-risk group in children with AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

7 January 2021

The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

7 January 2021

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

7 January 2021

c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

7 January 2021

Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

7 January 2021

Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

7 January 2021

Analysis of ras gene mutations in childhood myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

7 January 2021

RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

7 January 2021

C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

7 January 2021

In VivoDifferentiation of Mast Cells from Acute Myeloid Leukemia Blasts Carrying a Novel Activating Ligand-Independent C-kit Mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403870

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403870

1 reference

Dimensions Publication ID

20 September 2017

1033700089

0 references

1 reference